secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001493152-25-021758
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus reports Q3 loss per share $2.98, cash $5.8M; pauses enrollment pending Decoy20 combo efficacy
--------------------------------------------------------------------------------

- Q3 2025 loss per share $2.98 vs $9.04 YoY; cash $5.8M at Sept 30, expected to fund into Q1 2026.
- Completed Safety Lead-In cohort, dosing 6 participants with Decoy20 + tislelizumab; 3 stable disease, 2 remain on study.
- Enrollment paused pending additional efficacy evaluation and assessment of next development options.
- Raised $2.3M via ATM in September 2025; converted $5.7M promissory notes into stock/warrants in July.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315225021758/0001493152-25-021758-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315225021758/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-021758

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer